Bristol‑Myers Squibb: UBS Adjusts Price Target Ahead of Milvexian Data

The global biopharmaceutical company Bristol‑Myers Squibb (BMY), listed on the New York Stock Exchange, saw its valuation outlook updated by UBS on March 10, 2026. The Swiss brokerage firm raised its target price for the shares, citing forthcoming data on the company’s anticoagulant candidate Milvexian. The adjustment follows the release of preliminary results from ongoing clinical studies, which are expected to clarify Milvexian’s safety and efficacy profile.

UBS Price‑Target Revision

  • Date of update: March 10, 2026
  • Source: InsideMonkey (https://www.insidermonkey.com )
  • Key point: UBS lifted the target price for BMY shares in anticipation of Milvexian data.
  • Implication: The brokerage anticipates that positive findings could enhance BMY’s product pipeline and support future revenue growth.

Milvexian Context

Milvexian is an oral factor Xa inhibitor under investigation for the prevention of arterial and venous thrombosis. The company has been conducting phase 2 trials to evaluate its therapeutic potential. Although specific numerical outcomes are not disclosed in the announcement, UBS’s decision reflects confidence that the forthcoming data will strengthen BMY’s competitive positioning in the anticoagulant market.

Company Fundamentals

  • Market Capitalization: $123.7 billion
  • 52‑week High (March 1, 2026): $62.89
  • 52‑week Low (October 28, 2025): $42.52
  • Current Closing Price (March 11, 2026): $58.95
  • Price‑to‑Earnings Ratio: 17.17

Bristol‑Myers Squibb’s portfolio spans oncology, cardiovascular, immunology, and infectious disease therapeutics. Its focus on experimental therapies and established products underpins a diversified revenue stream.

Market Reaction

Following UBS’s announcement, BMY shares experienced a modest increase in trading volume, reflecting investor interest in the potential upside of Milvexian. The market remains attentive to the forthcoming clinical data, which is expected to arrive later in 2026.

Conclusion

UBS’s upward revision of Bristol‑Myers Squibb’s price target underscores the market’s expectation that Milvexian data will enhance the company’s growth prospects. Investors should monitor the trial results for definitive insight into the drug’s clinical value and its impact on BMY’s financial performance.